Loading...
Loading...
GMDA| Name | Value |
|---|---|
| Revenues | 1.1M |
| Cost of Revenue | 1.8M |
| Gross Profit | -0.7M |
| Operating Expense | 15.5M |
| Operating I/L | -16.2M |
| Other Income/Expense | 6.3M |
| Interest Income | 0.5M |
| Pretax | -8.8M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -8.8M |
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company specializing in the development of cell therapies for the treatment of blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, has completed Phase III clinical trials for high-risk hematologic malignancies and Phase I/II trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based cancer immunotherapy, through Phase I/II studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company's NK cell pipeline, including GDA-301, GDA-401, GDA-501, and GDA-601, aims to address hematologic malignancies and solid tumors.
